Replimune Group Inc [REPL] stock prices are up 1.94% to $12.32 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The REPL shares have gain 9.26% over the last week, with a monthly amount glided 29.87%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, ROTH MKM started tracking the stock with Buy rating on August 28, 2024, and set its price target to $17. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $52 on November 19, 2021. BTIG Research started tracking with a Buy rating for this stock on November 17, 2020, and assigned it a price target of $60. In a note dated November 02, 2020, Jefferies initiated an Buy rating and provided a target price of $67 on this stock.
The stock price of Replimune Group Inc [REPL] has been fluctuating between $6.44 and $17.00 over the past year. Currently, Wall Street analysts expect the stock to reach $27 within the next 12 months. Replimune Group Inc [NASDAQ: REPL] shares were valued at $12.32 at the most recent close of the market. An investor can expect a potential return of 119.16% based on the average REPL price forecast.
Analyzing the REPL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.58 and Total Capital is -0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Replimune Group Inc [NASDAQ:REPL]’s Current Ratio is 7.95. Also, the Quick Ratio is 7.95.
Transactions by insiders
Recent insider trading involved Astley-Sparke Philip, Director, that happened on May 20 ’25 when 32279.0 shares were sold. Chief Medical Officer, Xynos Konstantinos completed a deal on May 20 ’25 to sell 7952.0 shares. Meanwhile, Chief Accounting Officer Schwendenman Andrew sold 3287.0 shares on May 20 ’25.
